Morphological analysis of liver and kidneys of pregnant rats and their fetuses upon chronic Ritonavir administration;Análise morfológica dos fígados e rins no binômio materno-fetal após tratamento de ratas prenhes com Ritonavir durante toda a prenhez

Revista Brasileira de Ginecologia e Obstetricia

Volumn 29, Issue 7, 2007, Pages 346-351

  De Carvalho, Adelino Moreira ^a,e   Simões, Ricardo Santos ^b   Oliveira, Fábio Hideo Martins ^c   Simões, Manuel De Jesus ^b   Oliveira Filho, Ricardo Martins ^d   Nakamura, Mary Uchiyama ^b   Kulay Jr , Luiz ^b  

^a Universidade Jose do Rosario Vellano   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e NONE   (Brazil)

Author keywords

Anti retroviral agents; Kidney diseases chemically induced; Liver diseases chemically induced; Pregnancy, animal; Ritonavir adverse effects; Ritonavir toxicity

Indexed keywords

EID: 37449007956     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-72032007000700004     Document Type: Article

References (23)

1. Hokey DA, Weiner DB. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol. 2006; 28(3):267-79.
2. Dourado I, Veras MASM, Barreira D, Brito AM. Tendências da epidemia de Aids no Brasil após a terapia anti-retroviral. Rev Saúde Pública. 2006; 40 Supl.:9-17.
3. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001; 183(4):539-45.
4. Martinez AM, Hora VP, Santos AL, Mendoza-Sassi R, Von Groll A, Soares EA, D'Avila N, Silveira J, Leal RG, Tanuri A, Soares MA; HIV/AIDS Unit. Determinants of HIV-1 mother-to-child transmission in Southern Brazil. An Acad Bras Cienc. 2006; 78(1):113-21.
5. Germinario RJ. Anti-retroviral protease inhibitors - 'a two edged sword?' IUBMB Life. 2003; 55(2):67-70.
6. Kageyama M, Namiki H, Fukushima H, Terasaka S, Togawa T, Tanaka A, et al. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull. 2005; 28(1):130-7.
7. Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS. 2000; 14(10):1389-99.
8. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002; 346(24):1863-70.
9. Okong P. HIV/AIDS and women's health in Uganda: lingering gender inequity. J Obstet Gynaecol Can. 2006; 28(11):980-2.
10. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause to concern? Drug Saf. 2007; 30(3):203-13.
11. Hamilton JB, Wolfe JM. The effect of male hormone substances on birth and prenatal development in the rat. Anat Rec. 1938; 70:433-40.
12. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 1997; 25(4):489-501.
13. Carvalho AM, Oliveira-Filho RM, Simões MJ, Amed AA, Kulay L Jr. Effect of chronic ritonavir administration on pregnant rats and their fetuses. Clin Exp Obstet Gynecol. 2004; 31(3):229-31.
14. Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci. 2000; 918:287-97.
15. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995; 333(23):1534-9.
16. Picard O, Rosmorduc O, Cabane J. Hepatotoxicity associated with ritonavir. Ann Intern Med. 1998; 129(8):670-1.
17. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997; 176(2):478-89.
18. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004; 18(17):2277-84.
19. Duong M, Sgro C, Grappin M, Biron F, Boibieux A. Renal failure after treatment with ritonavir. Lancet. 1996; 348(9028):693.
20. Deray G, Bochet M, Katlama C, Bricaire F. Nephrotoxicity of ritonavir. Presse Med. 1998; 27(35):1801-3.
21. Hussain S, Khayat A, Tolaymat A, Rathore MH. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006; 21(7):1034-6.
22. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002; 16(17):2295-301.
23. Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J Pharmacol Exp Ther. 2003; 304(2):596-602.